Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511140-37-00

Acronym

DART

Enrollment

140

Registered

2024-04-09

Start date

2021-02-12

Completion date

Unknown

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OligoRecurrent prostate cancer

Brief summary

Metastasis-free survival

Detailed description

Clinical progression-free survival, Biochemical relapse-free survival, Time to next systemic therapy, Castrate resistant-free survival, Prostate cancer-specific survival, Overall survival, Acute and late toxicity, Quality of life

Interventions

DRUGBAY 1841788

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Metastasis-free survival	—

Secondary

Measure	Time frame
Clinical progression-free survival, Biochemical relapse-free survival, Time to next systemic therapy, Castrate resistant-free survival, Prostate cancer-specific survival, Overall survival, Acute and late toxicity, Quality of life	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026